Biblio
The timing of post-transplant cyclophosphamide administration in haploidentical transplantation: a comparative study on behalf of the ALWP of the EBMT. Biol Blood Marrow Transplant. 2020.
Successful "on-demand" plerixafor for autologous peripheral blood stem-cells transplantation for relapsed/refractory germ cell tumors. J Clin Apher. 2021.
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. J Clin Oncol. 2023:JCO2201784.
Peripheral blood hemopoietic stem cell mobilization regimens in POEMS syndrome: a retrospective study at two haematological Italian centres. Biol Blood Marrow Transplant. 2019.
Peripheral Blood Allogeneic Stem Cell Mobilization: Can We Predict a Suboptimal Mobilization?. Transfus Med Rev. 2023;37(2):150725.
Late HBV reactivation after hematopoietic stem cell transplantation, despite long-term prophylaxis. Eur J Clin Microbiol Infect Dis. 2023.
. . Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: long-term follow up of a phase III study. Am J Hematol. 2020.
Impact of second-degree related donor on the outcomes of T cell-replete haploidentical transplantation with post-transplant cyclophosphamide. Bone Marrow Transplant. 2022.
The impact of graft CD3/Tregs ratio on aGvHD and post-transplant outcome: a prospective multicenter study on patients with acute leukemia undergoing allogeneic peripheral blood stem cell transplantation. Transplant Cell Ther. 2021.
Impact of donor age and kinship on clinical outcomes after T-cell-replete haploidentical transplantation with PT-Cy. Blood Adv. 2020;4(16):3900-3912.
Impact of Covid 19 pandemic on hematopoietic stem cell transplantation activities: Report from a single center. Transfus Apher Sci. 2023:103708.
. Haploidentical transplantation in primary refractory/relapsed secondary versus de novo AML: from the ALWP/EBMT. Blood Adv. 2024.
GITMO REGISTRY STUDY ON ALLOGENEIC TRANSPLANTATION IN PATIENTS AGED OVER 60 FROM 2000 TO 2017. IMPROVEMENTS AND CRITICISMS. Transplant Cell Ther. 2021.
Full Donor Chimerism After Allogeneic Hematopoietic Stem Cells Transplant For Myelofibrosis: The Role Of The Conditioning Regimen. Am J Hematol. 2020.
ECP versus ruxolitinib in steroid-refractory chronic GVHD - a retrospective study by the EBMT transplant complications working party. Bone Marrow Transplant. 2024.
ECP versus ruxolitinib in steroid-refractory acute GVHD - a retrospective study by the EBMT transplant complications working party. Front Immunol. 2023;14:1283034.
Discrepancy between recipient and donor rs4364254 heparanase single nucleotide polymorphism impacts graft-versus-host disease after allogeneic stem cell transplant. Int J Lab Hematol. 2023.
. Day100 Score predicts moderate-severe cGVHD, transplant mortality, and survival after hematopoietic cell transplantation. Blood Adv. 2021.
Clinical reversible myelopathy in T-cell lymphoblastic lymphoma treated with nelarabine and radiotherapy: report of a case and review of literature of an increasing complication. Mediterr J Hematol Infect Dis. 2015;7(1):e2015025.
. BH3 mimetics in relapsed and refractory adult acute lymphoblastic leukemia: a Campus ALL real-life study. Haematologica. 2023.